Synaptogenix shares are trading higher after the company announced an abstract featuring secondary endpoint data of its NIH-sponsored Phase 2 Bryostatin-1 trial was accepted for presentation at the 11th IBRO World Congress of Neuroscience.
Portfolio Pulse from Benzinga Newsdesk
Synaptogenix has announced that an abstract featuring secondary endpoint data of its NIH-sponsored Phase 2 Bryostatin-1 trial has been accepted for presentation at the 11th IBRO World Congress of Neuroscience. This news has led to an increase in the company's share price.
July 13, 2023 | 3:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Synaptogenix's shares are trading higher after the company announced its Phase 2 Bryostatin-1 trial data was accepted for presentation at a major neuroscience congress.
The acceptance of Synaptogenix's Phase 2 Bryostatin-1 trial data for presentation at a major neuroscience congress is a positive development for the company. This news indicates progress in their research and development efforts, which can be seen as a positive signal by investors, leading to an increase in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100